Cite
MLA Citation
N. Yamamoto et al.. “Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.” Lung cancer, vol. 151, 2021, pp. 20–24. http://access.bl.uk/ark:/81055/vdc_100119342800.0x000039